Debut Biotechnology, a California-based startup engaged in biotech beauty, has launched BeautyORB, an artificial intelligence (AI)-powered innovation engine.
BeautyORB is designed to discover new ingredients for beauty brands.
The platform is intended to accelerate biotech innovation for all beauty brands globally via a partnership with KDC/one, a contract manufacturer.
According to Debut Biotechnology, which is a University of California, Irvine (UCI) spinout, BeautyORB can help introduce two new ingredients annually, speeding up the development process.
The genomics-based AI platform uses pharmaceutical-grade technology to create new ingredients. These innovations target inflammageing, epidermal barrier repair, longevity, brightening, anti-ageing, and scalp care.
BeautyORB advances ingredient discovery by screening 50 billion molecules to activate cellular pathways within the skin.
Debut Biotechnology claimed that its AI platform has already identified three patented ingredients that surpass existing benchmarks and meet the highest beauty standards.
One of the ingredients is DermCeutical InflammagePRO, which is designed for inflammaging, reducing inflammatory markers. This ingredient can strengthen the skin barrier, thereby enhancing elasticity.
DermCeutical InflammagePRO is said to be 15X more effective than niacinamide.
The second ingredient, DermCeutical Barrier RepairPRO, is intended for epidermal barrier repair, defending the skin from environmental damage and repairing skin 30% better than vitamin C, the biotech beauty said.
DermCeutical LongevityPRO, the third ingredient, according to the company, leads to cellular longevity by decreasing markers of cellular ageing and maintaining healthy skin cells, outperforming vitamin C.
Debut Biotechnology founder and CEO Joshua Britton said: “With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction.
“This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims.
“We don’t have to rely on an array of existing ingredients to test against specific claims, and we don’t have to go into the field to find rare ingredients in plants.”
In July last year, Debut Biotechnology launched BiotechXBeautyLabs, a formulation development and contract manufacturing business.
BiotechXBeautyLabs creates next-generation sustainable biotech products with custom formulations and a range of clinically backed white-label options.
In November, the business entered the professional beauty services market and signed its first partnership with Formula Fig.
